Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK and Capecitabine in Advanced Breast Cancer
NCT02491697Phase 2Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Feb 2016
- Primary completion
- Aug 2030
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 2, randomised, open-label trial of dendritic cell vaccine + cytokine-induced killer cells in breast cancer, sponsored by Changzhou First People's Hospital. Started Feb 2016; status: active, not recruiting.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02491697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491697.